Case Based Roundtable Logo

This roundtable series explores options for anemic patients with myelofibrosis after they have received a JAK inhibitor, as discussed by key opinion leaders and participants at virtual live events.

Symptomatic Patients With Myelofibrosis Treated Post-JAK Inhibition

Transfusion Independence With Momelotinib Impacts OS in Myelofibrosis
Transfusion Independence With Momelotinib Impacts OS in Myelofibrosis
January 11, 2024
During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed dosing of JAK inhibitors therapy and how the survival data for ruxolitinib compares with that of momelotinib. This is the second of 2 articles based on this event.
Importance of Early Start to Therapy and SCT Referral in Myelofibrosis
Importance of Early Start to Therapy and SCT Referral in Myelofibrosis
December 19, 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Haris Ali, MD, and participants discussed approaches to starting JAK inhibitor therapy for a patient with myelofibrosis and when to refer for stem cell transplant. This is the first of 2 articles based on this event.
Trials Support Use of Momelotinib After JAK Inhibition for Anemic MF
Trials Support Use of Momelotinib After JAK Inhibition for Anemic MF
November 21, 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed data from the SIMPLIFY-2 and MOMENTUM trials of momelotinib for patients with myelofibrosis. This is the second of 2 articles based on this event.
Momelotinib Impacts Treatment Methods for Anemia in Myelofibrosis
Momelotinib Impacts Treatment Methods for Anemia in Myelofibrosis
September 15, 2023
Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.